Dr Bavanthi Balakrishnar

Research Fellow, Medical Oncology
Medicine, Westmead Clinical School


Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Kloth, J., Klumpen, H., Yu, H., Eechoute, K., Samer, C., Kam, B., Huitema, A., Daali, Y., Zwinderman, A., Balakrishnar, B., Wong, M., Gurney, H., et al (2014). Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study. Clinical Pharmacokinetics, 53(3), 261-269. [More Information]
  • Gao, B., Yeap, S., Clements, A., Balakrishnar, B., WONG, M., Gurney, H. (2012). Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. Journal of Clinical Oncology, 30(32), 4017-4025. [More Information]

Conferences

  • Balakrishnar, B. (2013). Profiling endoxifen levels in invasive breast cancer patients on tamoxifen. COSA 38th Annual Scientific Meeting, United Kingdom: Wiley-Blackwell Publishing Ltd.
  • Balakrishnar, B. (2012). Bladder Cancer Concept: Safety of Cisplatin in patients with renal impairment and invasive urothelial cancer. 2012 ANZUP Annual Scientific Meeting, United Kingdom: Wiley-Blackwell Publishing Ltd.

2014

  • Kloth, J., Klumpen, H., Yu, H., Eechoute, K., Samer, C., Kam, B., Huitema, A., Daali, Y., Zwinderman, A., Balakrishnar, B., Wong, M., Gurney, H., et al (2014). Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study. Clinical Pharmacokinetics, 53(3), 261-269. [More Information]

2013

  • Balakrishnar, B. (2013). Profiling endoxifen levels in invasive breast cancer patients on tamoxifen. COSA 38th Annual Scientific Meeting, United Kingdom: Wiley-Blackwell Publishing Ltd.

2012

  • Balakrishnar, B. (2012). Bladder Cancer Concept: Safety of Cisplatin in patients with renal impairment and invasive urothelial cancer. 2012 ANZUP Annual Scientific Meeting, United Kingdom: Wiley-Blackwell Publishing Ltd.
  • Gao, B., Yeap, S., Clements, A., Balakrishnar, B., WONG, M., Gurney, H. (2012). Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. Journal of Clinical Oncology, 30(32), 4017-4025. [More Information]

To update your profile click here. For support on your academic profile contact .